George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.smaller Cos. Regulatory News (BSV)

Share Price Information for Br.smaller Cos. (BSV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 80.00
Bid: 78.50
Ask: 81.50
Change: 0.00 (0.00%)
Spread: 3.00 (3.822%)
Open: 80.00
High: 81.50
Low: 80.00
Prev. Close: 80.00
BSV Live PriceLast checked at -
British Smaller Companies VCT is an Investment Trust

To maximise Total Return and provide investors with an attractive long-term tax-free dividend yield while maintaining the Company's status as a venture capital trust.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

1st Quarter Results

13 Sep 2023 07:00

RNS Number : 2903M
British Smaller Companies VCT PLC
13 September 2023
 

British Smaller Companies VCT plc

Interim Management Statement

For the quarter ended 30 June 2023

British Smaller Companies VCT plc (the "Company") presents its interim management statement for the quarter ended 30 June 2023. The statement also includes relevant financial information between the end of the quarter and the date of this statement. A copy of this interim management statement can be found at www.bscfunds.com.

Overview

In the quarter to 30 June 2023, the Company's Net Asset Value per share return was unchanged at 83.7 pence. In comparison, the FTSE Small Cap Index fell by 0.4 per cent during the period. AIC data ranks the Company first across all generalist VCTs when considering a blended average performance ranking over 1, 3, 5, 7 and 10 years.

The Company's Total Return at 30 June 2023 was unchanged at 258.6 pence per ordinary share.

During the quarter, the Company invested £2.6 million into Workbuzz, an employee insights and engagement settlement platform. The Company also invested a further £0.8 million into Relative Insight.

The Company realised its investment in Ncam in April, generating initial proceeds of £1.4 million. There is the potential for additional receipts of up to £1.2 million depending on the achievement of certain milestones over the coming years, which would see the Company fully recover its investment; £0.3 million of deferred proceeds have been recognised at the period end.

Subsequent to the period end, the Company has made a further investment of £0.3 million into Elucidat.

Performance

The table below sets out movements in key metrics for the Company. 

 

 

31 March 2023

Increase in Value

Shares issued

Buyback of shares

Movement

In Period

30 June 2023

Net Assets (£m)

157.0

0.4

44.4

(0.4)

44.4

201.4

NAV per share (PPS)

83.7

0.2

(0.2)

-

-

83.7

Cumulative dividends paid (PPS)

174.9

-

-

-

-

174.9

Total Return (PPS)

258.6

0.2

(0.2)

-

-

258.6

Shares in issue

187,679,279

-

53,559,905

(451,965)

53,107,940

240,787,219

Cumulative dividends paid at 30 June 2023 were unchanged at 174.9 pence per ordinary share (31 March 2023: 174.9 pence per ordinary share).

The movements in NAV and NAV per ordinary share are set out in the table below:

 

 

£m

Pence per

ordinary share

NAV at 31 March 2023

157.0

83.7

Increase in portfolio value

0.6

0.3

Net operating costs

(0.2)

(0.1)

0.4

0.2

Issue/buy-back of shares*

44.0

(0.2)

Total Return in the period

44.4

-

NAV at 30 June 2023

 

201.4

 

83.7

 

* The allotment of shares from the 2022/23 fundraising reduced total return per ordinary share as the fundraising was priced at the last reported NAV at the time of the allotment of 82.8 pence per ordinary share, being the NAV as at 31 December 2022 of 87.3 pence per ordinary share, adjusted for the special interim dividend of 4.5 pence per ordinary share paid on 11 January 2023.

 

Post-period end, on 28 July 2023, a dividend of 2.0 pence per ordinary share for the year ending 31 March 2024 was paid, resulting in a corresponding reduction to the 30 June 2023 unaudited NAV, to 81.7 pence per ordinary share.

Dividends and shares in issue

On 4 April 2023, the Company allotted 53,559,905 shares following the close of its 2022/23 fundraising.

Under its standing buyback authority, on 26 June 2023 the Company purchased 451,965 shares at 80.02 pence at a cost of £0.36 million. These shares are held in treasury. 

Subsequent to the quarter end, on 28 July 2023 the Company issued 1,270,231 shares under the Company's Dividend Re-investment Scheme (DRIS) following the payment of the interim dividend, taking the number of shares in issue at that date to 242,057,450, with a further 22,459,730 shares held in treasury.

Net assets

Net assets at 30 June 2023 comprised the following:

£000

% of net assets

Unquoted investments at fair value

125,850

62.5

Listed investment funds

3,745

1.9

Cash and cash equivalents

69,854

34.7

Other net assets

1,993

0.9

Net assets

201,442

100.0

Investments

The investment portfolio at 30 June 2023 comprised:

Valuation

£000

Cumulative valuation as a % of net assets

Matillion

24,886

12.4%

Unbiased

10,511

17.6%

Displayplan

8,829

22.0%

Outpost

8,680

26.3%

Wooshii

6,981

29.7%

Elucidat

6,226

32.8%

Force24

4,758

35.2%

Vypr

4,159

37.2%

ACC Aviation

4,095

39.3%

Quality Clouds

4,032

41.3%

 

83,157

41.3%

Other investments

42,693

21.2%

Total investments

125,850

62.5%

Portfolio performance

Over the quarter to 30 June 2023, the aggregate unquoted portfolio valuation has increased by £0.8 million.

Fundraising

On 4 April 2023 the Company allotted shares from its fully subscribed 2022-23 share offer. £44.4 million was raised by the Company, resulting in the allotment of 53,559,905 ordinary shares.

On 2 August 2023, the Company announced its intention to launch a joint offer for subscription for the 2023-24 tax year later this year, alongside British Smaller Companies VCT2 plc. A prospectus with full details of the proposed Offer is expected to be published in mid-to-late September.

Outlook

Portfolio companies continue to show resilience in navigating a challenging macro environment, charting a path that balances continued growth with a move towards profitability. While rising interest rates will slow economic growth, a more capital constrained environment reduces competition and alternative funding sources, providing opportunities for further deployment of capital for the Company, in both new and existing portfolio companies. In this vein, the Company continues to see a healthy pipeline of opportunities in which to invest in fast growing British businesses.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU No. 596/2014). Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

13 September 2023

For further information please contact:

David Hall YFM Private Equity Limited Tel: 0113 244 1000

Alex Collins Panmure Gordon (UK) Limited Tel: 0207 886 2767

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRFEALNDFAXDEEA
Date   Source Headline
3rd Apr 20247:58 amRNSIssue of Equity and Close of Offers
26th Mar 202411:11 amRNSTransaction in Own Shares and Total Voting Rights
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
15th Mar 202412:15 pmRNS3rd Quarter Results
16th Feb 20243:52 pmRNSClose of Offers to New Applications
16th Feb 20243:51 pmRNSClose of Offers to New Applications
30th Jan 20249:23 amRNSIssue of Equity
18th Dec 20234:02 pmRNSTransaction in Own Shares
13th Dec 20234:00 pmRNSOffer Update
13th Dec 20234:00 pmRNSStrategy/Company/Ops Update
8th Dec 20239:47 amRNSPayment of Dividend and Issue of Equity
24th Nov 20237:00 amRNSHalf-year Report
26th Oct 20231:34 pmRNSDividend Declaration
24th Oct 20231:20 pmRNSOffer Update
24th Oct 20231:19 pmRNSOffer Update
6th Oct 202310:19 amRNSOffer Update
6th Oct 202310:17 amRNSOffer Update
27th Sep 20238:21 amRNSOffer Update
26th Sep 20238:20 amRNSTransaction in Own Shares and PDMR
20th Sep 202312:30 pmRNSPublication of a Prospectus
20th Sep 202312:30 pmRNSPublication of a Prospectus
14th Sep 202310:28 amRNSResult of AGM
14th Sep 202310:28 amRNSResult of General Meeting
13th Sep 20237:00 amRNS1st Quarter Results
2nd Aug 202310:25 amRNSNew combined offer for subscription
2nd Aug 202310:25 amRNSNew combined offer for subscription
28th Jul 202310:00 amRNSDirector/PDMR Shareholding
28th Jul 202310:00 amRNSPayment of Dividend and Issue of Equity
27th Jun 20237:45 amRNSTransaction in Own Shares
21st Jun 20231:00 pmRNSPublication of Circular
16th Jun 202312:00 pmRNSAnnual Financial Report
4th Apr 20233:24 pmRNSDirector/PDMR Shareholding
4th Apr 20233:23 pmRNSIssue of Equity and Close of Offers
29th Mar 20238:42 amRNSTransaction in Own Shares
27th Mar 20236:00 pmRNSClose of Offers to new Applications
27th Mar 20236:00 pmRNSClose of Offers to new Applications
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
20th Mar 20233:00 pmRNS3rd Quarter Results
14th Feb 20234:35 pmRNSOffer Update
14th Feb 20234:35 pmRNSOffer Update
11th Jan 202310:00 amRNSDirector/PDMR Shareholding
11th Jan 202310:00 amRNSPayment of Dividend and Issue of Equity
19th Dec 20228:48 amRNSTransaction in Own Shares
6th Dec 20229:58 amRNSOffer Update
6th Dec 20229:58 amRNSOffer Update
30th Nov 202212:30 pmRNSPublication of a Prospectus
30th Nov 202212:30 pmRNSPublication of a Prospectus
25th Nov 20229:30 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.